- Home
- IFRX vs FATBP Comparison
IFRX vs FATBP Comparison
Compare IFRX & FATBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IFRX
- FATBP
- Stock Information
- Founded
- IFRX 2007
- FATBP N/A
- Country
- IFRX Germany
- FATBP United States
- Employees
- IFRX N/A
- FATBP 7390
- Industry
- IFRX Biotechnology: Pharmaceutical Preparations
- FATBP Restaurants
- Sector
- IFRX Health Care
- FATBP Consumer Discretionary
- Exchange
- IFRX Nasdaq
- FATBP Nasdaq
- Market Cap
- IFRX 120.1M
- FATBP N/A
- IPO Year
- IFRX 2017
- FATBP N/A
- Fundamental
- Price
- IFRX $2.06
- FATBP $9.25
- Analyst Decision
- IFRX Strong Buy
- FATBP
- Analyst Count
- IFRX 1
- FATBP 0
- Target Price
- IFRX $8.00
- FATBP N/A
- AVG Volume (30 Days)
- IFRX 266.7K
- FATBP N/A
- Earning Date
- IFRX 11-08-2024
- FATBP N/A
- Dividend Yield
- IFRX N/A
- FATBP N/A
- EPS Growth
- IFRX N/A
- FATBP N/A
- EPS
- IFRX N/A
- FATBP N/A
- Revenue
- IFRX $187,930.00
- FATBP N/A
- Revenue This Year
- IFRX $311.47
- FATBP N/A
- Revenue Next Year
- IFRX $227.11
- FATBP N/A
- P/E Ratio
- IFRX N/A
- FATBP N/A
- Revenue Growth
- IFRX 177.12
- FATBP N/A
- 52 Week Low
- IFRX $1.17
- FATBP N/A
- 52 Week High
- IFRX $2.44
- FATBP N/A
- Technical
- Relative Strength Index (RSI)
- IFRX 67.23
- FATBP 32.66
- Support Level
- IFRX $1.51
- FATBP $9.13
- Resistance Level
- IFRX $2.15
- FATBP $9.32
- Average True Range (ATR)
- IFRX 0.24
- FATBP 0.15
- MACD
- IFRX 0.05
- FATBP 0.00
- Stochastic Oscillator
- IFRX 60.42
- FATBP 17.91
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
About FATBP FAT Brands Inc. 8.25% Series B Cumulative Preferred Stock
FAT Brands Inc is a multi-brand restaurant franchising company. It develops, markets, acquires and manages quick service, fast casual, casual dining, and polished casual dining restaurant concepts around the world. The company operates as a franchisor of restaurants, where the company generally does not own or operate the restaurant locations but rather generates revenue by charging franchisees an initial franchise fee as well as ongoing royalties. For some of the company's brands, it also directly owns and operates restaurant locations. Its brands include Round Table Pizza, Fatburger, Johnny Rockets, Twin Peaks, and Elevation Burger among others. Geographically, the majority of the revenue for the company is generated from the United States and the rest from other countries.